

### Supplementary Figure S1: Optimization of PI3P detection and analysis of control lipids in AD brains.

**a to d**) HPLC separation of deacylated PI4P and PI3P. **a**) The HPLC elution profile described in Nasuhoglu et. al. 2002 was unable to sufficiently separate PI3P from PI4P in a mixed internal standard preparation. The approximate elution time of PI4P and PI3P is indicated by the arrow. **b**) The HPLC elution profile was modified with a flatter elution gradient to enable separation of PI3P from PI4P. The approximate elution time of PI4P and PI3P and PI3P is indicated by the arrow. **c**) Representative elution spectra of a prefrontal cortex control sample. **d**) The same prefrontal cortex sample spiked with PI3P internal standard.



# Supplementary Figure S2: APP is associated with Vps34- and Pl3P-positive endosomes.

**a)** Confocal analysis of HeLa cells transfected with Vps34<sup>RFP</sup>, APP<sup>myc</sup> and FYVE-FYVE<sup>GFP</sup>, fixed and labeled with anti-myc antibody. Insets 1 and 2 show magnifications where all three proteins are present on the same membranous structures (empty arrowheads). Scale bar = 10µm. **b)** Confocal analysis of HeLa cells transfected with Vps34<sup>RFP</sup>, fixed and labeled with anti-EEA1 and anti-LAMP1 antibodies. Solid and empty arrowheads indicate colocalization in membranous structures between Vps34<sup>RFP</sup> and the early endosomal marker EEA1 and the late endosomal marker Lamp1, respectively. Scale bar = 10µm.



### Supplementary Figure S3: Analysis of the subcellular localization of APPRFP.

**a)** Confocal analysis of HeLa cells transfected with APP<sup>RFP</sup> and labeled with the indicated antibodies. Colocalizations between APP<sup>RFP</sup> and the early endosomal marker EEA1 are indicated (orange arrowheads) as well as those between APP<sup>RFP</sup> and the late endosomal marker LAMP1 (blue arrowheads). **b)** Confocal analysis of HeLa cells transfected with APP<sup>RFP</sup> and labeled with the indicated antibodies. APP<sup>RFP</sup> colocalized with EEA1 and late Golgi marker giantin, as illustrated by quantification of relative RFP fluorescence colocalization with EEA1 or giantin (right panel, n = 30 cells). **c)** Total endosomal fraction was prepared from HeLa cells transfected with APP<sup>RFP</sup> and analyzed by Western blot with anti-Rab7 and -RFP antibodies. Endosomal fraction represents 1/10 of the loaded post nuclear supernatant (PNS) in terms of total protein amount. Full length APP<sup>RFP</sup> and its cleavage products [COOH-terminal Fragments (CTFs) and the APP intracellular domain (AICD) are shown. **d)** Confocal analysis of HeLa cells transfected with APP<sup>RFP</sup> and starved for 1 h in the absence (upper panel) or presence (baf, lower panel) of 50 nM bafilomycin A1, before labeling with an anti-LC3 antibody. For a, b, d, scale bar = 10µm.



Supplementary Figure S4: Electron and light microscopic analysis of endogenous and exogenously expressed APP. a) Immunogold EM analysis of HeLa cells transfected with APP<sup>GFP</sup> and labeled with an anti-GFP antibody. Arrowheads indicate APP<sup>GFP</sup> inside the lumen of endosomal structures. Scale bar=0.3  $\mu$ m. b) Confocal analysis of mouse hippocampal neurons (DIV14) labeled with antibodies to endogenous APP (APP-Cter) and the indicated antibodies. Pictures emphasize naturally occuring enlarged endolysosomal structures showing luminal APP cytodomain. Scale bar=0.4 $\mu$ m. c and d) Confocal analysis of HeLa cells transfected with APP<sup>RFP</sup> and Rab5<sub>Q79L</sub><sup>GFP</sup> (Rab5<sub>Q</sub><sup>GFP</sup>), and treated with 10 $\mu$ M cycloheximide (CHX) for 3h at 37°C. In (c), cells were then incubated for 20 min with an antibody to the N-terminal ectodomain of APP (22C11) at 4°C to label the cell surface pool of APP (left panel, confocal acquisition of basal plane; right panel, nuclear plane). In (d), cells were then submitted to a chase phase of 15 min (left panel) or 30 min (right panel) with medium at 37°C , prior to confocal analysis. Scale bar=10 $\mu$ m.

a



### Supplementary Figure S5: Effect of wortmannin on PI3P and the endosomal pool of APPRFP.

a) Confocal analysis of HeLa cells transfected with APPRFP and FYVE-FYVEGFP and subjected to a treatment with vehicle (upper panel) or 100nM wortmannin (lower panel), prior to immunolabeling with the indicated antibodies. Scale bar = 10µm. b) Confocal analysis of HeLa cells transfected with APPRFP and Rab5<sub>Q79L</sub>GFP and treated with vehicle (MOCK) or 100nM wortmannin. Upper panel, confocal images showing mock-treated (left) and wortmannin-treated (right) cells. Scale bar = 5µm. Lower panel, quantification of the endosomal distribution of APPRFP after wortmannin treatment, expressed as % of total APPRFP: internal = inside endosomal lumen, peripheral = limiting membrane of the endosomes. Values denote means ± SEM (n = 10 cells from 3 experiments with an average guantification of 15 endosomes per cell); asterisks denote P values < 0.001 (from a Student's t-test).



### Supplementary Figure S6: Effect of Vps34 silencing on PI3P levels and the localization of endosomal markers.

**a)** Confocal analysis of HeLa cells either Mock-transfected (Mock) or transfected with siRNAs to Vps34 for 72h (siVps34), prior to labeling with a purified FYVE-FYVE-GST fusion protein and staining with a fluorescently-labeled anti-GST antibody and DAPI. Scale bar =  $40\mu$ m. **b)** Quantification of the total FYVE-FYVE-GST fluorescence from cells shown in (a), expressed in arbitrary units (A.U.) (n=4); asterisks denote P values < 0.001 (from a Student's *t*-test). **c)** Confocal analysis of HeLa cells either Mock-transfected (Mock) or transfected with siRNAs to Vps34 for 72h (siVps34), followed by a second transfection with FYVE-FYVE<sup>GFP</sup>. Arrowheads indicate FYVE-FYVE<sup>GFP</sup> positive-cells. Scale bar =  $60\mu$ m. **d)** Confocal analysis of HeLa cells processed as in (a), but labeled with antibodies to endosomal markers, EEA1 and Vps35. Scale bar =  $20\mu$ m.



## Supplementary Figure S7: Distribution of APP<sup>RFP</sup> in Rab5<sub>Q79L</sub><sup>GFP</sup> endosomes after silencing of Vps34, Hrs, Tsg101, SNX3 or Beclin1.

**a**) Representative Western blots showing decreased levels of Hrs, Tsg101, SNX3 and Beclin1 in the corresponding knockdowns after 72 h. Actin is used as loading marker. **b**) Confocal pictures from the Hrs, Tsg101, SNX3 and Beclin1 knockdowns showing the accumulation of APP<sup>RFP</sup> on the limiting membrane of enlarged endosomes in the Hrs, Tsg101 and SNX3 knockdowns, in contrast to the Mock control and the Beclin1 knockdown, where the fluorescence of APP<sup>RFP</sup> is predominantly luminal. Scale bar = 10µm. **c**) Quantification of the endosomal distribution of APP<sup>RFP</sup> in HeLa cells after transfection for 72 h with siRNAs to Vps34, Hrs, Tsg101, SNX3 or Beclin1, followed by a second transfection with APP<sup>RFP</sup> and Rab5<sub>Q79L</sub><sup>GFP</sup> constructs. Cells were analyzed by confocal microscopy 24 h later. The localization of APP<sup>RFP</sup> inside the endosomal lumen (internal) or on the endosomal limiting membrane (peripheral) was quantified and expressed as % of the total endosomal APP<sup>RFP</sup>. Values denote means ± SEM (n=66, 43, 43, 31, 50, and 35 cells for the MOCK, Vps34, Hrs, Tsg101, SNX3 and Beclin1 knockdowns, respectively; from a pool of 5 experiments, with an average of approximately 15 endosomes per cell). Asterisks denote P values < 0.01 (\*\*) (from a one-way ANOVA with post-hoc Tukey test).



## Supplementary Figure S8: Subcellular distribution of the 3R APP mutant in primary neurons in relation to the Vps35-positive compartment.

Mouse hippocampal neurons were transfected with  $APP_{wt}^{GFP}$  (in **a**) or  $APP_{3R}^{GFP}$  (in **b**) at DIV9. After 24h in the presence (right panels) or absence (left panels) of  $\gamma$ -secretase inhibitor XXI, neurons were stained with an anti-Vps35 antibody (red) and imaged with confocal microscopy. Scale bar = 10 µm. Arrowheads indicate areas of colocalization between  $APP^{GFP}$  and Vps35. **c**) Quantification of the colocalization between  $APP^{GFP}$  and Vps35 measured in colocalization area per 2500µm<sup>2</sup> image area. Values denote means ± SEM (n = 26 cells); asterisks denote P values < 0.001 (from a Student's *t*-test).



#### Supplementary Figure S9: Subcellular distribution of the 3R mutant in primary neurons in relation to the GM130-positive compartment.

Mouse hippocampal neurons were transfected with  $APP_{wt}^{GFP}$  (in **a**) or  $APP_{3R}^{GFP}$  (in **b**) at DIV9. After 24h in the presence (right panels) or absence (left panels) of  $\gamma$ -secretase inhibitor XXI, neurons were stained with an anti-GM130 antibody (red) and imaged with confocal microscopy. Scale bar = 10 µm. Arrowheads indicate areas of colocalization between  $APP^{GFP}$  and GM130. **c**) Quantification of the colocalization between  $APP^{GFP}$  and GM130 measured in colocalization area per 2500µm<sup>2</sup> image area. Values denote means ± SEM (n = 37 cells); Asterisks denote P values < 0.001 (from a Student's *t*-test).



note

Supplementary Figure S10: Full scans or digital pictures of immuno-blots shown in figures 1-8